House Energy & Commerce Committee Chief Health Counsel Clay Alspach provided an update on timing for full House consideration of the 21st Century Cures bill, during a Catalyst-moderated panel June 17. This article also notes that the panel, held at the DIA annual meeting, featured comments  from CDER Director Janet Woodcock on unfunded FDA provisions in the bill, including in the area of medical devices. Woodcock’s comments on the patient-focused drug development provisions of 21st Century Cures are also highlighted.

Cures Bill Heads to Floor Vote with FDA Funding Worry